Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Virpax Pharmaceuticals Inc (NQ: VRPX )

1.665 +0.385 (+30.08%)
Streaming Delayed Price Updated: 12:02 PM EDT, Jul 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Virpax Pharmaceuticals Inc

< Previous 1 2 3 Next >
Virpax® Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference
From Virpax® Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Recaps Milestones and Highlights Product Portfolio
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Announces Clinical Trial Site in Canada for First in Human Study of Epoladerm™ for Pain Associated with Osteoarthritis of the Knee
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Reports Successful Results of Toxicology and Pharmacokinetic Study for Epoladerm™
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Reports 2021 Third Quarter Results and Recent Developments
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Advances Envelta™ Development with NCATS Under CRADA Agreement
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Signs Agreement with Sinclair Research to Initiate Investigational New Drug (IND)-Enabling Studies for AnQlar™
From Virpax Pharmaceuticals Inc.
Via Business Wire
Virpax to Present at the NobleCon Online Pain Management Investor Forum on Channelchek.com on October 7, 2021
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax to Develop Intranasal Cannabidiol Product for the Management of Epilepsy in Adults and Children
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax® Pharmaceuticals Announces Closing of $40 Million Public Offering of Common Stock
From Virpax Pharmaceuticals Inc.
Via Business Wire
Virpax® Pharmaceuticals Announces Pricing of $40 Million Public Offering of Common Stock
From Virpax Pharmaceuticals Inc.
Via Business Wire
Virpax Pharmaceuticals Announces Poster Presentation for Envelta™ at PAINWeek 2021
From Virpax Pharmaceuticals
Via Business Wire
Virpax Announces MMS019 Manufacturing and Supply Agreement
From Virpax® Pharmaceuticals, Inc.
Via Business Wire
Virpax® Pharmaceuticals Receives FDA Response and Guidance on MMS019
From Virpax® Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Reports 2021 Second Quarter Results and Recent Developments
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax® Pharmaceuticals Strengthens Board of Directors with the Appointment of Gerald W. Bruce and Michael F. Dubin, CPA to its Board
From Virpax Pharmaceuticals
Via Business Wire
Virpax Pharmaceuticals Provides Progress Update on Product Candidates
From Virpax Pharmaceuticals Inc.
Via Business Wire
Virpax to Use Envelta™ IND Enabling Study Results for Two Additional Indications
From Virpax Pharmaceuticals
Via Business Wire
Virpax Pharmaceuticals to Present at LD Micro Invitational XI Event on Wednesday, June 9th at 4:30 PM ET
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Reports 2021 First Quarter Results and Recent Developments
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Engages Torreya Capital to Advise on Global Partnering Efforts
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax’s MMS019 Reduced Nasal and Brain Viral Load in Animal Study
From Virpax Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.